Fri Apr 25 16:33:38 SGT 2014  
    Smoking Cessation, Uganda

Smoking Cessation, Uganda


Smoking Cessation, Uganda @beautyuganda_com: Quit/stop smoking with the medication Champix®. Smoking cessation clinic, Uganda. Private and confidential services. Definitions, references, and latest news.

Keywords: Smoking Cessation Uganda, Uganda Smoking Cessation, Smoking Cessation.


Quit smoking with the medication Champix®. Revolutionary new way to stop smoking at our smoking cessation clinic. Get away from the harmful effects of smoking, without feeling the effects of withdrawal!

Advertisement: Come to sunny Singapore to have your testing and treatment. Singapore Ministry of Health registered general practice (GP) clinic:
168 Bedok South Avenue 3 #01-473
Singapore 460168
Tel: (+65) 6446 7446
Fax: (+65) 6449 7446
24hr Answering Tel: (+65) 6333 5550
Web: Smoking Cessation, Uganda
Opening Hours
Monday to Friday: 9 am to 3 pm, 7 pm to 11 pm
Saturday & Sunday: 7 pm to 11 pm
Public Holidays: Closed
Last registration: one hour before closing time.
Walk-in clinic. Appointments not required.
Bring NRIC, Work Pass or Passport for registration.


Latest News

Review: Nicotine replacement therapy increases CVD events; bupropion and varenicline do not.
Tue, 15 Apr 2014 00:00:00 +0100 | Annals of Internal Medicine
Authors: Rowland K

Diverse strategies targeting α7 homomeric and α6β2* heteromeric nicotinic acetylcholine receptors for smoking cessation
Mon, 14 Apr 2014 00:00:00 +0100 | Annals of the New York Academy of Sciences
Preclinical studies suggest that a diversity of nicotinic acetylcholine receptors (nAChRs) with different sensitivities to nicotine may contribute to tobacco addiction. Using rodent intravenous nicotine self‐administration as a preclinical model with good predictive validity for therapeutic efficacy for tobacco cessation, investigators have identified heteromeric α6β2* and homomeric α7 nAChRs as promising novel therapeutic targets to promote smoking abstinence (*denotes possible assembly with other subunits). The data suggest that diverse strategies that target these subclasses of nAChRs, namely inhibition of α6β2* nAChRs and stimulation of α7 nAChRs, will support tobacco cessation. α6β2* nAChRs, members of the high‐affinity family of β2* nAChRs, function similarly to α4β2* ...

Table of Contents
Thu, 10 Apr 2014 06:29:15 +0100 | The Brown University Psychopharmacology Update

Drug effects on multiple and concurrent schedules of ethanol‐ and food‐maintained behavior: context dependent selectivity
Fri, 04 Apr 2014 00:00:00 +0100 | British Journal of Pharmacology
Conclusions and implicationsResults are consistent with those seen following fluvoxamine and varenicline administration, and suggest that selectivity is assay‐dependent. These results indicate the need for careful interpretation of selective drug effects, especially when obtained in situations where ethanol or the alternative is the only programmed reinforcement available. (Source: British Journal of Pharmacology)

No age discrimination pledge in drugs appraisals
Fri, 28 Mar 2014 00:00:00 +0100 | OnMedica Latest News
NICE launches consultation on how it assesses drugs and treatments Related items from OnMedicaStart varenicline sooner to boost successSleeping pills linked to fourfold death riskNew guidance for elderly with high BP‘Scorecards’ will eradicate NHS drug inequalitySugar not saturated fat is the major issue for CVD (Source: OnMedica Latest News)

Interventions for preoperative smoking cessation.
Thu, 27 Mar 2014 00:00:00 +0100 | Cochrane Database of Systematic Reviews
CONCLUSIONS: There is evidence that preoperative smoking interventions providing behavioural support and offering NRT increase short-term smoking cessation and may reduce postoperative morbidity. One trial of varenicline begun shortly before surgery has shown a benefit on long-term cessation but did not detect an effect on early abstinence or on postoperative complications. The optimal preoperative intervention intensity remains unknown. Based on indirect comparisons and evidence from two small trials, interventions that begin four to eight weeks before surgery, include weekly counselling and use NRT are more likely to have an impact on complications and on long-term smoking cessation.

Twelve weeks of smoking cessation therapy with varenicline increases the serum levels of apolipoprotein A-I only in the success group.
Mon, 24 Mar 2014 00:00:00 +0100 | Journal of Cardiology
CONCLUSION: These findings suggest that successful smoking cessation therapy with varenicline improves serum apoA-I and HDL-C levels in the short term.

General Practitioner prescribing of single and combination nicotine replacement therapy in the UK: A retrospective database study
Thu, 20 Mar 2014 00:00:00 +0100 | Epidemiologic Perspectives and Innovations

Effects of varenicline, nicotine or placebo on depressive symptoms in postmenopausal smokers.
Sat, 15 Mar 2014 00:00:00 +0100 | American Journal on Addictions
CONCLUSION: CESD score were lower in those receiving varenicline, whether this is due to an anti-depressant effect, subject selection, use of relaxation or another cause is unknown. Varenicline does not increase depressive symptoms during smoking cessation in postmenopausal women without current MDD. Subjects with a LH-MDD are susceptible to developing depressive symptoms during smoking cessation, regardless of pharmacologic aid.

Varenicline decreases ethanol intake and increases dopamine release via neuronal nicotinic acetylcholine receptors in the nucleus accumbens
Fri, 14 Mar 2014 00:00:00 +0100 | British Journal of Pharmacology
CONCLUSIONS AND IMPLICATIONSFollowing long‐term ethanol consumption, varenicline in the NAc reduces ethanol intake suggesting that pre‐synaptic nAChRs in the NAc are important for mediating varenicline's effects on ethanol consumption. (Source: British Journal of Pharmacology)